- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Int J Biol Sci. 2016 Aug 5;12(9):1104-13. doi: 10.7150/ijbs.16064. eCollection 2016.
An Effective Molecular Target Site in Hepatitis B Virus S Gene for Cas9 Cleavage and Mutational Inactivation.Li H1, Sheng C1, Liu H1, Liu G2, Du X1, Du J3, Zhan L3, Li P1, Yang C1, Qi L1, Wang J1, Yang X1, Jia L1, Xie J1, Wang L1, Hao R1, Xu D4, Tong Y5, Zhou Y5, Zhou J6, Sun Y1, Li Q7, Qiu S1, Song H1.
Author information
- 1Institute of Disease Control and Prevention, Academy of Military Medical Sciences, Beijing, China.
- 2Transgenic Engineering Research Laboratory, Infectious Disease Center, Guangzhou 458 th Hospital, Guangzhou, China.
- 3Lab of Blood-Borne Viruses, Beijing Institute of Transfusion Medicine, Beijing, China.
- 4Research Center for Liver Failure, Beijing 302 nd Hospital, Beijing, China.
- 5State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
- 6Gladcan Consulting Company, Beijing, China.
- 7Department of Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
AbstractChronic hepatitis B infection remains incurable because HBV cccDNA can persist indefinitely in patients recovering from acute HBV infection. Given the incidence of HBV infection and the shortcomings of current therapeutic options, a novel antiviral strategy is urgently needed. To inactivate HBV replication and destroy the HBV genome, we employed genome editing tool CRISPR/Cas9. Specifically, we found a CRISPR/Cas9 system (gRNA-S4) that effectively targeted the HBsAg region and could suppress efficiently viral replication with minimal off-target effects and impact on cell viability. The mutation mediated by CRISPR/Cas9 in HBV DNA both in a stable HBV-producing cell line and in HBV transgenic mice had been confirmed and evaluated using deep sequencing. In addition, we demonstrated the reduction of HBV replication was caused by the mutation of S4 site through three S4 region-mutated monoclonal cells. Besides, the gRNA-S4 system could also reduce serum surface-antigen levels by 99.91 ± 0.05% and lowered serum HBV DNA level below the negative threshold in the HBV hydrodynamics mouse model. Together, these findings indicate that the S4 region may be an ideal target for the development of innovative therapies against HBV infection using CRISPR/Cas9.
KEYWORDS: CRISPR/Cas9; HBV infection
PMID:27570484DOI:10.7150/ijbs.16064
|
|